Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$101.51
-1.49-1.45%
At close: -
$101.51
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
Blueprint Medicines Analyst Ratings and Price Targets | NASDAQ:BPMC | Benzinga
Blueprint Medicines Corp has a consensus price target of $118.16 based on the ratings of 26 analysts. The high is $168 issued by Goldman Sachs on May 6, 2024. The low is $43 issued by SVB Leerink on June 5, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Needham, and Wedbush on May 2, 2025, April 28, 2025, and April 16, 2025, respectively. With an average price target of $131 between HC Wainwright & Co., Needham, and Wedbush, there's an implied 29.05% upside for Blueprint Medicines Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Needham
Wedbush
Morgan Stanley
Jefferies
1calculated from analyst ratings
Analyst Ratings for Blueprint Medicines
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/02/2025 | Buy Now | 32.99% | HC Wainwright & Co. | Andrew Fein54% | $135 → $135 | Reiterates | Buy → Buy | Get Alert |
| 04/28/2025 | Buy Now | 28.07% | Needham | Ami Fadia53% | $133 → $130 | Maintains | Buy | Get Alert |
| 04/16/2025 | Buy Now | 26.1% | Wedbush | David Nierengarten43% | $128 → $128 | Reiterates | Outperform → Outperform | Get Alert |
| 04/08/2025 | Buy Now | 31.02% | Needham | Ami Fadia53% | $133 → $133 | Reiterates | Buy → Buy | Get Alert |
| 03/20/2025 | Buy Now | -1.49% | Morgan Stanley | Judah Frommer63% | $120 → $100 | Assumes | → Equal-Weight | Get Alert |
| 03/17/2025 | Buy Now | 32.99% | Jefferies | Michael Yee49% | → $135 | Initiates | → Buy | Get Alert |
| 03/07/2025 | Buy Now | 47.77% | Scotiabank | Louise Chen29% | → $150 | Initiates | → Sector Outperform | Get Alert |
| 03/03/2025 | Buy Now | 23.14% | Citizens Capital Markets | Reni Benjamin51% | $125 → $125 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/14/2025 | Buy Now | 23.14% | JMP Securities | Reni Benjamin51% | $125 → $125 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/14/2025 | Buy Now | 31.02% | Needham | Ami Fadia53% | $133 → $133 | Reiterates | Buy → Buy | Get Alert |
| 02/14/2025 | Buy Now | 32.99% | HC Wainwright & Co. | Andrew Fein54% | $135 → $135 | Reiterates | Buy → Buy | Get Alert |
| 02/13/2025 | Buy Now | 31.02% | Needham | Ami Fadia53% | $133 → $133 | Reiterates | Buy → Buy | Get Alert |
| 02/04/2025 | Buy Now | 27.08% | JP Morgan | Brian Cheng49% | $126 → $129 | Maintains | Overweight | Get Alert |
| 01/27/2025 | Buy Now | 17.23% | Piper Sandler | Christopher Raymond57% | $109 → $119 | Maintains | Neutral | Get Alert |
| 01/15/2025 | Buy Now | 23.14% | JMP Securities | Reni Benjamin51% | $125 → $125 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 01/13/2025 | Buy Now | 22.16% | Wedbush | David Nierengarten43% | $135 → $124 | Reiterates | Outperform → Outperform | Get Alert |
| 01/13/2025 | Buy Now | 32.99% | Needham | Ami Fadia53% | $135 → $135 | Reiterates | Buy → Buy | Get Alert |
| 01/02/2025 | Buy Now | 37.92% | Stephens & Co. | Sudan Loganathan14% | $140 → $140 | Reiterates | Overweight → Overweight | Get Alert |
| 12/17/2024 | Buy Now | 32.99% | Needham | Ami Fadia53% | $135 → $135 | Reiterates | Buy → Buy | Get Alert |
| 12/11/2024 | Buy Now | — | Guggenheim | Michael Schmidt58% | — | Reiterates | Buy → Buy | Get Alert |
| 12/09/2024 | Buy Now | 23.14% | JMP Securities | Reni Benjamin51% | $125 → $125 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 11/18/2024 | Buy Now | 23.14% | JMP Securities | Reni Benjamin51% | $125 → $125 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 11/15/2024 | Buy Now | 32.99% | HC Wainwright & Co. | Andrew Fein54% | $135 → $135 | Reiterates | Buy → Buy | Get Alert |
| 11/15/2024 | Buy Now | 32.99% | Needham | Ami Fadia53% | $135 → $135 | Reiterates | Buy → Buy | Get Alert |
| 11/14/2024 | Buy Now | 24.13% | JP Morgan | Brian Cheng49% | → $126 | Initiates | → Overweight | Get Alert |
| 10/31/2024 | Buy Now | 48.75% | Wells Fargo | Derek Archila70% | $153 → $151 | Maintains | Overweight | Get Alert |
| 10/31/2024 | Buy Now | 32.99% | HC Wainwright & Co. | Andrew Fein54% | $135 → $135 | Reiterates | Buy → Buy | Get Alert |
| 10/31/2024 | Buy Now | 32.99% | Needham | Ami Fadia53% | $133 → $135 | Maintains | Buy | Get Alert |
| 10/30/2024 | Buy Now | 31.02% | Needham | Ami Fadia53% | $133 → $133 | Reiterates | Buy → Buy | Get Alert |
| 10/24/2024 | Buy Now | -13.31% | UBS | David Dai71% | → $88 | Initiates | → Neutral | Get Alert |
| 08/05/2024 | Buy Now | 31.02% | Needham | Ami Fadia53% | $130 → $133 | Maintains | Buy | Get Alert |
| 08/02/2024 | Buy Now | 35.95% | Guggenheim | Michael Schmitz64% | $130 → $138 | Maintains | Buy | Get Alert |
| 08/02/2024 | Buy Now | 25.11% | Baird | Joel Beatty69% | $112 → $127 | Maintains | Outperform | Get Alert |
| 08/01/2024 | Buy Now | 28.07% | Needham | Ami Fadia53% | $130 → $130 | Reiterates | Buy → Buy | Get Alert |
| 07/29/2024 | Buy Now | 3.44% | Barclays | Peter Lawson58% | $75 → $105 | Maintains | Equal-Weight | Get Alert |
| 07/12/2024 | Buy Now | 13.29% | Morgan Stanley | Michael Ulz24% | $110 → $115 | Maintains | Equal-Weight | Get Alert |
| 07/08/2024 | Buy Now | 23.14% | Oppenheimer | Matthew Biegler42% | $114 → $125 | Maintains | Outperform | Get Alert |
| 06/28/2024 | Buy Now | 28.07% | Needham | Ami Fadia53% | $130 → $130 | Reiterates | Buy → Buy | Get Alert |
| 06/07/2024 | Buy Now | 23.14% | JMP Securities | Reni Benjamin51% | $125 → $125 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/14/2024 | Buy Now | 37.92% | Stephens & Co. | Sudan Loganathan14% | → $140 | Initiates | → Overweight | Get Alert |
| 05/06/2024 | Buy Now | -4.44% | Leerink Partners | Andrew Berens48% | $50 → $97 | Upgrade | Underperform → Market Perform | Get Alert |
| 05/06/2024 | Buy Now | 65.5% | Goldman Sachs | Terence Flynn61% | $121 → $168 | Maintains | Buy | Get Alert |
| 05/03/2024 | Buy Now | -25.13% | Citigroup | David Lebowitz53% | $65 → $76 | Maintains | Sell | Get Alert |
| 05/03/2024 | Buy Now | 32.99% | HC Wainwright & Co. | Andrew Fein54% | $125 → $135 | Maintains | Buy | Get Alert |
| 05/03/2024 | Buy Now | 23.14% | JMP Securities | Reni Benjamin51% | $114 → $125 | Maintains | Market Outperform | Get Alert |
| 05/03/2024 | Buy Now | -26.12% | Barclays | Peter Lawson58% | $70 → $75 | Maintains | Equal-Weight | Get Alert |
| 05/03/2024 | Buy Now | 2.45% | Piper Sandler | Christopher Raymond57% | $78 → $104 | Maintains | Neutral | Get Alert |
| 05/03/2024 | Buy Now | 28.07% | Needham | Ami Fadia53% | $97 → $130 | Maintains | Buy | Get Alert |
| 05/02/2024 | Buy Now | -4.44% | Needham | Ami Fadia53% | $97 → $97 | Reiterates | Buy → Buy | Get Alert |
| 04/26/2024 | Buy Now | 23.14% | HC Wainwright & Co. | Andrew Fein54% | $125 → $125 | Reiterates | Buy → Buy | Get Alert |
| 04/26/2024 | Buy Now | 8.36% | Wedbush | David Nierengarten43% | $110 → $110 | Reiterates | Outperform → Outperform | Get Alert |
| 04/26/2024 | Buy Now | -4.44% | Needham | Ami Fadia53% | $97 → $97 | Reiterates | Buy → Buy | Get Alert |
| 04/26/2024 | Buy Now | 28.07% | Stifel | Bradley Canino39% | $120 → $130 | Maintains | Buy | Get Alert |
| 04/10/2024 | Buy Now | 12.3% | JMP Securities | Reni Benjamin51% | $114 → $114 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/26/2024 | Buy Now | -4.44% | Needham | Ami Fadia53% | $97 → $97 | Reiterates | Buy → Buy | Get Alert |
| 02/16/2024 | Buy Now | 12.3% | JMP Securities | Reni Benjamin51% | $114 → $114 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/16/2024 | Buy Now | -35.97% | Citigroup | David Lebowitz53% | $54 → $65 | Maintains | Sell | Get Alert |
| 02/13/2024 | Buy Now | -31.04% | Barclays | Peter Lawson58% | $58 → $70 | Maintains | Equal-Weight | Get Alert |
| 01/16/2024 | Buy Now | 12.3% | JMP Securities | Reni Benjamin51% | $114 → $114 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 01/09/2024 | Buy Now | -4.44% | Stifel | Bradley Canino39% | $95 → $97 | Maintains | Buy | Get Alert |
| 12/22/2023 | Buy Now | -1.49% | Raymond James | Dane Leone55% | $85 → $100 | Maintains | Strong Buy | Get Alert |
| 12/19/2023 | Buy Now | 13.29% | Wells Fargo | Derek Archila70% | $86 → $115 | Maintains | Overweight | Get Alert |
| 12/11/2023 | Buy Now | -16.26% | HC Wainwright & Co. | Andrew Fein54% | $85 → $85 | Reiterates | Buy → Buy | Get Alert |
| 10/27/2023 | Buy Now | -16.26% | Oppenheimer | Matthew Biegler42% | → $85 | Upgrade | Perform → Outperform | Get Alert |
| 10/27/2023 | Buy Now | -37.94% | Morgan Stanley | Michael Ulz24% | $59 → $63 | Maintains | Equal-Weight | Get Alert |
| 10/27/2023 | Buy Now | -42.86% | Barclays | Peter Lawson58% | $46 → $58 | Maintains | Equal-Weight | Get Alert |
| 10/27/2023 | Buy Now | -27.1% | Needham | Ami Fadia53% | $66 → $74 | Maintains | Buy | Get Alert |
| 08/21/2023 | Buy Now | -34.98% | Needham | Ami Fadia53% | $65 → $66 | Maintains | Buy | Get Alert |
| 08/07/2023 | Buy Now | 12.3% | JMP Securities | Reni Benjamin51% | → $114 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 08/03/2023 | Buy Now | -41.88% | Morgan Stanley | Michael Ulz24% | $55 → $59 | Maintains | Equal-Weight | Get Alert |
| 08/03/2023 | Buy Now | -18.23% | Goldman Sachs | Terence Flynn61% | $93 → $83 | Maintains | Buy | Get Alert |
| 08/03/2023 | Buy Now | -35.97% | Needham | Ami Fadia53% | → $65 | Reiterates | Buy → Buy | Get Alert |
| 08/03/2023 | Buy Now | -16.26% | HC Wainwright & Co. | Andrew Fein54% | → $85 | Reiterates | Buy → Buy | Get Alert |
| 08/02/2023 | Buy Now | -35.97% | Needham | Ami Fadia53% | → $65 | Reiterates | Buy → Buy | Get Alert |
| 07/31/2023 | Buy Now | — | Wells Fargo | Derek Archila70% | — | Upgrade | Equal-Weight → Overweight | Get Alert |
| 07/14/2023 | Buy Now | -45.82% | Morgan Stanley | Michael Ulz24% | $55 → $55 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 06/14/2023 | Buy Now | -45.82% | Wells Fargo | Derek Archila70% | $48 → $55 | Maintains | Equal-Weight | Get Alert |
| 06/05/2023 | Buy Now | -57.64% | SVB Leerink | Andrew Berens48% | $48 → $43 | Downgrade | Market Perform → Underperform | Get Alert |
| 05/23/2023 | Buy Now | -19.22% | Guggenheim | Michael Schmidt58% | $78 → $82 | Maintains | Buy | Get Alert |
| 05/23/2023 | Buy Now | -26.12% | Wedbush | Liana Moussatos78% | → $75 | Reiterates | Outperform → Outperform | Get Alert |
| 05/23/2023 | Buy Now | 12.3% | JMP Securities | Reni Benjamin51% | → $114 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/23/2023 | Buy Now | -52.71% | Wells Fargo | Derek Archila70% | $47 → $48 | Maintains | Equal-Weight | Get Alert |
| 05/23/2023 | Buy Now | -16.26% | HC Wainwright & Co. | Andrew Fein54% | $75 → $85 | Maintains | Buy | Get Alert |
| 05/23/2023 | Buy Now | -34% | Needham | Ami Fadia53% | $65 → $67 | Maintains | Buy | Get Alert |
| 05/23/2023 | Buy Now | -54.68% | Barclays | Peter Lawson58% | $44 → $46 | Maintains | Equal-Weight | Get Alert |
| 05/05/2023 | Buy Now | -45.82% | Morgan Stanley | Michael Ulz24% | $50 → $55 | Maintains | Equal-Weight | Get Alert |
| 05/05/2023 | Buy Now | 12.3% | JMP Securities | Reni Benjamin51% | → $114 | Reiterates | → Market Outperform | Get Alert |
| 05/05/2023 | Buy Now | -26.12% | HC Wainwright & Co. | Andrew Fein54% | $70 → $75 | Maintains | Buy | Get Alert |
| 05/05/2023 | Buy Now | -35.97% | Needham | Ami Fadia53% | $56 → $65 | Maintains | Buy | Get Alert |
| 04/19/2023 | Buy Now | -43.85% | Needham | Ami Fadia53% | → $57 | Reiterates | → Buy | Get Alert |
| 03/30/2023 | Buy Now | 12.3% | JMP Securities | Reni Benjamin51% | → $114 | Reiterates | → Market Outperform | Get Alert |
| 02/28/2023 | Buy Now | 12.3% | JMP Securities | Reni Benjamin51% | → $114 | Reiterates | → Market Perform | Get Alert |
| 02/28/2023 | Buy Now | -43.85% | Needham | Ami Fadia53% | → $57 | Reiterates | → Buy | Get Alert |
| 02/28/2023 | Buy Now | -31.04% | HC Wainwright & Co. | Andrew Fein54% | → $70 | Reiterates | → Buy | Get Alert |
| 02/27/2023 | Buy Now | -43.85% | Needham | Ami Fadia53% | → $57 | Reiterates | → Buy | Get Alert |
| 02/24/2023 | Buy Now | -62.57% | SVB Leerink | Andrew Berens48% | $45 → $38 | Maintains | Market Perform | Get Alert |
| 02/17/2023 | Buy Now | -16.26% | Raymond James | Dane Leone55% | $115 → $85 | Maintains | Strong Buy | Get Alert |
| 02/17/2023 | Buy Now | -31.04% | HC Wainwright & Co. | Andrew Fein54% | → $70 | Reiterates | → Buy | Get Alert |
| 02/17/2023 | Buy Now | -43.85% | Needham | Ami Fadia53% | $60 → $57 | Maintains | Buy | Get Alert |
| 02/16/2023 | Buy Now | -40.89% | Needham | Ami Fadia53% | → $60 | Reiterates | → Buy | Get Alert |
FAQ
What is the target price for Blueprint Medicines (BPMC) stock?
The latest price target for Blueprint Medicines (NASDAQ:BPMC) was reported by HC Wainwright & Co. on May 2, 2025. The analyst firm set a price target for $135.00 expecting BPMC to rise to within 12 months (a possible 32.99% upside). 39 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Blueprint Medicines (BPMC)?
The latest analyst rating for Blueprint Medicines (NASDAQ:BPMC) was provided by HC Wainwright & Co., and Blueprint Medicines reiterated their buy rating.
When was the last upgrade for Blueprint Medicines (BPMC)?
The last upgrade for Blueprint Medicines Corp happened on May 6, 2024 when Leerink Partners raised their price target to $97. Leerink Partners previously had an underperform for Blueprint Medicines Corp.
When was the last downgrade for Blueprint Medicines (BPMC)?
The last downgrade for Blueprint Medicines Corp happened on June 5, 2023 when SVB Leerink changed their price target from $48 to $43 for Blueprint Medicines Corp.
When is the next analyst rating going to be posted or updated for Blueprint Medicines (BPMC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Blueprint Medicines, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Blueprint Medicines was filed on May 2, 2025 so you should expect the next rating to be made available sometime around May 2, 2026.
Is the Analyst Rating Blueprint Medicines (BPMC) correct?
While ratings are subjective and will change, the latest Blueprint Medicines (BPMC) rating was a reiterated with a price target of $135.00 to $135.00. The current price Blueprint Medicines (BPMC) is trading at is $101.51, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
